Zentalis Restructures To Advance Late-Stage Cancer Drug Development
Zentalis focuses on late-stage development of azenosertib, optimizing resources to extend its cash runway.
Breaking News
Jan 29, 2025
Simantini Singh Deo
.png)
Zentalis Pharmaceuticals, a biotech firm specializing in developing treatments for cancer, has released the restructuring of its operations for prioritizing late-stage development on one of its most promising agents in the form of a WEE1 inhibitor known as azenosertib. The restructuring ensures the company raises sufficient funds for continuing research and its completion of the key clinical study named the DENALI Part 2, for which the outcome is to be expected by the end of 2026.
Julie Eastland, Chief Executive Officer, said in a statement, "Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynaecological malignancies. To support this goal, we have made the necessary decisions to efficiently organize our company and allocate our capital resources to extend the cash runway beyond an anticipated azenosertib data readout that we believe has the potential to be registration-enabling. I want to thank all the individuals departing the Company for their valuable contributions to all Zentalis programs and the development of azenosertib. Tomorrow morning, we look forward to hosting a corporate event to share updated azenosertib clinical data and provide a development and regulatory update, including plans for our registration-intent studies, as we work to bring this therapeutic candidate forward to patients as quickly as possible.”
Zentalis will host a virtual event on January 29, 2025, at 8:00 AM ET. to share the updates. During the event, the company will present new data on azenosertib and provide insights into its development and regulatory plans. The live webcast or access a recorded version later will be available on the company’s website under the “Events & Presentations” section.